Navigation Links
Valeant Pharmaceuticals to Announce 2011 Third Quarter Results on November 3, 2011
Date:10/21/2011

MISSISSAUGA, Ontario, Oct. 21, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Thursday, November 3, 2011 at 10:00 a.m. ET (7:00 a.m. PT) to discuss results for the 2011 third quarter.

The dial-in number to participate on this call is (877) 295-5743, confirmation code 18668216.  International callers should dial (973) 200-3961, confirmation code 18668216. A replay will be available approximately two hours following the conclusion of the conference call to Thursday, November 10, 2011, and can be accessed by dialing (855) 859-2056 or (404) 537-3406, confirmation code 18668216.

The webcast and slide presentation will be hosted in the investor relations section of its corporate Web site at www.valeant.com. Participants should allow approximately five to 10 minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the Internet webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at www.valeant.com.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant can be found at www.valeant.com.

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada
2. Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share
3. Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities
4. Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa
5. Valeant Pharmaceuticals to Present at Industry Conferences
6. Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program
7. Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid
8. Valeant Pharmaceuticals Completes Acquisition of Sanitas Group
9. Valeant Pharmaceuticals Announces Resignation of Michael Van Every From Valeants Board of Directors
10. Valeant Pharmaceuticals Reports 2011 Second Quarter Financial Results
11. Valeant Pharmaceuticals Announces Approval of Sublinox® in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... , May 23, 2017  Leaf Healthcare, recognized ... medical devices for pressure ulcer prevention, will unveil ... Association of Critical Care Nurses, National Teaching Institute ... The Leaf Patient Monitoring System is ... the hospital environment.  The system seamlessly tracks patient ...
(Date:5/18/2017)... 17, 2017  Bayer announced today that the latest ... presented at the 53 rd Annual Meeting of ... June 2-6 in Chicago . ... prostate, colorectal, liver and thyroid cancers, as well as ... II CHRONOS-1 trial of copanlisib in patients with relapsed ...
(Date:5/11/2017)... May 11, 2017  Thornhill Research Inc. ( ... awarded an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract ... Canadian Commercial Corporation (CCC) ( Ottawa, Ontario, ... to administer general anesthesia to patients requiring emergency ... "The US Marine Corps have been a longtime ...
Breaking Medicine Technology:
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... Maass Medical Center CEO Mary Ellen, hospital employees, and town officials to celebrate ... , The facility was developed by Rendina as part of its ongoing relationship ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD ... New York City. He is known for his distinguished expertise and experience in the ... Benvenisty holds sub-specialty training in treating renovascular disease and aortic aneurysm . He ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... medical image management and interpretation, has received U.S. Food and Drug Administration (FDA) ... is a web-based, scalable and secure cloud platform for medical image management. At ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Manju R. Kejriwal, a leading ... orthodontics, with or without a referral. Dr. Kejriwal understands the emotional and financial toll ... braces in Cincinnati, OH. Patients no longer need to feel the esthetic effects of ...
(Date:5/24/2017)... ... May 24, 2017 , ... STATEMENT OPPOSING PRESIDENT ... opposed to Donald Trump’s budget, “A New Foundation for American Greatness—President's Budget FY ... the poor, marginalizes underserved populations, undermines productivity, and destroys the social safety net ...
Breaking Medicine News(10 mins):